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Abstract
Human papillomavirus (HPV) is a sexually transmitted infection contributing to 70% of
oropharyngeal cancers in the United States. The incidence of HPV-related oropharyngeal
cancers is greater in Kentucky’s population than in any other state. Research has
demonstrated the cost of treating oropharyngeal cancer on a national level, but little
information exists as to state-specific costs. The purpose of this quantitative study was to
examine radiation therapy costs for treating HPV-related oropharyngeal cancer in
Kentucky in relation to age, gender, race, and insurance. A theory by Aday and Andersen
was applied to explain the relationship between the independent and dependent variables.
Cluster sampling was used to randomly select 130 de-identified men and women age 4065 years who had been diagnosed with oropharyngeal cancer. The data were collected
from an existing database. The study used descriptive analysis with correlational,
longitudinal data to examine the relationship of categorical and continuous variables. The
mean cost for radiation therapy treatment was $123,629.14 (SD= $58,697.36). The
multiple regression indicated that the null hypothesis was accepted showing that the
independent variables were not statistically significant predictors of the z Score of Cost
Difference [F (4,122) = 0.972, p = 0.425]. The results showed no significant independent
predictor variables (p > 0.05); gender [t (127) = -0.943, p = 0.348], race [t (127) = 1.378,
p = 0.171], insurance type [t (127) = -1.512, p = 0.133], and age group [t (127) = -0.230,
p = 0.818]). The results may contribute to positive social change in the development of
cancer prevention strategies and policies.
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Section 1: Foundation of the Study
Introduction
Head and neck cancer is a serious disease that affects many people worldwide.
Head and neck cancers account for over 333,000 deaths each year globally and over
11,000 deaths in the United States annually (Jones, Fekrazad, & Bauman, 2013). Cancers
originating from the paranasal sinuses, nasal cavity, salivary glands, oral cavity,
oropharynx, nasopharynx, hypopharynx, and larynx are referred to as head and neck
cancers (Denson, Janitz, Brame, & Campbell, 2016; Howard & Chung, 2012; Maasland,
van de Brandt, Kremer, Goldbohm, & Schouten, 2014). Oropharyngeal cancer is a form
of head and neck cancer that forms in the cells of tissue of the middle part of the throat
(pharynx; National Cancer Institute, n.d., 2015). Oropharyngeal cancer rates are
increasing, with data suggesting that human papillomavirus (HPV) may be an important
causal reason for this rise (D’Souza & Dempsey, 2011). It is estimated that 20 million
people are currently infected with HPV (Lewis, Kang, Levine, & Maghami, 2015).
Potentially 6.2 million new cases will occur annually worldwide in the coming years
(Lewis et al., 2015). Oropharyngeal cancer is the second most common HPV-associated
cancer deserving attention for future interventions (Centers for Disease Control and
Prevention [CDC], 2017). The impact of HPV on oropharyngeal cancer is of concern.
HPV-related oropharyngeal cancer is increasing worldwide, affecting people at a younger
age.
The link between HPV and oropharyngeal cancers is currently being researched.
Approximately 30,000 people worldwide with oropharyngeal cancers are also diagnosed
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with HPV, which is detected in 25% of all head and neck cancers in the United States
(D’Souza & Dempsey, 2011). HPV contributes to 70% of oropharyngeal cancers in the
United States (Lewis et al., 2015). The population with oropharyngeal cancers is younger
than those with tobacco-mediated cancers (Lewis et al., 2015). Historically,
oropharyngeal cancers were diagnosed in older males who abused tobacco and alcohol,
but currently oral cancer is affecting those under the age of 40 years (Lewis et al., 2015).
The exact incidence of HPV-positive oropharyngeal cancer is unknown and could be
misrepresented because current practice does not support testing all oropharyngeal
cancers for HPV status (Boggs, 2015). HPV as a risk factor alone may not be sufficient to
cause oropharyngeal cancers. More research is needed to investigate whether other risk
factors along with HPV cause oropharyngeal cancers. Although research has occurred
worldwide on this topic, little research has been completed using state-specific data in the
United States. Kentucky has some of the highest HPV-related cancer rates in the nation,
including rates of oropharyngeal cancer (Kaprowy, 2012). Therefore, the problem that I
explored in this study was the impact of costs associated with treating oropharyngeal
cancer in Kentucky on health systems. Addressing HPV through studies such as this one
may help inform efforts to lower the number of HPV-related oropharyngeal cancers and
reduce associated cost burdens on health care systems.
Kentucky’s population demonstrates a higher incidence of HPV-related
oropharyngeal cancer compared to other states (CDC, 2017). Understanding the burden
of HPV and oropharyngeal cancer within this population is necessary. The data in this
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study may provide information on the economic burden of HPV-related oropharyngeal
cancer.
Problem Statement
Cancer is a major cost driver in the U.S. health care system. In 2017 in the United
States, 1.7 million new cancer cases were diagnosed (American Cancer Society [ACS],
2017). The economic impact of cancers is significant. In 2014, $87.8 billion was spent on
cancer in the United States. (ACS, 2017). Health care costs have risen to approximately
$2 trillion, with the costs of cancer representing $200 billion (Lyman, 2017). Specific
types of cancers, such as oropharyngeal cancer, have a unique impact upon the U.S.
health system. The 5-year invasive incidence rates for HPV-related oropharyngeal
cancers are 11.0 per 100,000 persons in the United States and 13.6 per 100,000 persons in
Kentucky (Kentucky Cancer Registry [KCR], 2016). The mortality rates are 2.5 per
100,000 persons for the U.S. and 2.8 per 100,000 persons for Kentucky (KCR, 2016).
These statistics could provide data for policy recommendations for the Kentucky
population.
Purpose
The purpose of this study was to use secondary data to examine the costs of
radiation therapy for treating HPV-related oropharyngeal cancer based on age, gender,
race, HPV status, and insurance in Kentucky. Twenty-five percent of Kentucky’s adult
population consists of smokers (AE&A, 2017). Tobacco use is linked to 85% of
oropharyngeal cancers (AE&A, 2017). The primary risk factor for oropharyngeal cancer
is oral HPV (Osazuwa-Peters et al., 2015). Oral HPV is considered a sexually transmitted
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disease (AE&A, 2017). The disease has been linked to sexual behaviors such as early age
at coitus, multiple partners, oral sex, and kissing (Osazuwa-Peters et al., 2015). Males
and Blacks have a higher incidence of oropharyngeal cancer compared to females and
Whites. Oropharyngeal cancer has not been recognized as an indicator for HPV
vaccination (Ward, Mehta, & Moore, 2016). The link between HPV and oropharyngeal
cancer could present health care organizations and health care leaders in Kentucky with
opportunities to address cost drivers such as HPV in cancer diagnoses.
Research Question
RQ. Is there a significant predictive relationship between patient gender, age,
insurance type, and race and the increased cost of radiation therapy associated with HPVrelated oropharyngeal cancer in Kentucky?
H01:

There is no significant predictive relationship between patient gender, age,
insurance type, and race and the increased cost of radiation therapy
associated with HPV-related oropharyngeal cancer in Kentucky.

Ha1:

There is a significant predictive relationship between patient gender, age,
insurance type, and race and the increased cost of radiation therapy
associated with HPV-related oropharyngeal cancer in Kentucky.

The secondary data types considered to answer the research question were
deidentified data on newly diagnosed patients with oropharyngeal cancer at a cancer
center in Louisville, Kentucky. Data extracted for this study were from 2010 to 2016.
These years were chosen because data on HPV-associated oropharyngeal cancer were not
collected before 2009. During the period from 2010 to 2016, there were 1,654 newly
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diagnosed head and neck cancers in this population, and the number of people diagnosed
with oropharyngeal cancers was 628. Of the 628 cases of oropharyngeal cancer that were
diagnosed, 208 cancers were associated with HPV. For data on costs, I used previous
literature and Current Procedural Terminology (CPT) codes from cancer center electronic
medical records.
Theoretical Foundation for the Study
The framework for this study was based on a theory by Aday and Andersen
(1974) that provides a causal structure for utilization and cost associated with health
services. Aday and Andersen’s theory may be used to explain costs related to
predisposing factors, enabling factors, and need factors. The independent variables for
this study were the predisposing factors of age, race, gender, and HPV status; the
enabling factor of insurance; and the needs factor of oropharyngeal cancer. The
dependent variable was cost. Different versions of the Aday and Andersen model have
been used in studies on predisposing factors such as age, marital status, gender/sex,
education, ethnicity/nativity, and employment status (Babitsch, Gohl, & von Lengeke,
2012). Enabling factors in these studies have included income/financial situation, health
insurance, source of care/family doctor, and availability of medical services/inpatient and
outpatient care facilities (Babitsch et al., 2012). Need factors have included health status,
self-reported/perceived health, diabetes, depression, hypertension, heart disease, and
cancer (Babitsch et al., 2012).
Kepka, Smith, Zeruto, & Yabroff (2014) presented a study using Aday and
Andersen’s theory as a framework to describe how healthcare utilization is influenced by
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health policies, delivery systems, and population characteristics as they impact access to
health services. The independent variable in the study by Kepka et al. was medical
provider. The dependent variables were cancer screening, HPV vaccination, and cancer
prevention recommendations. The characteristics used in this study were similar to those
used in my study; such as insurance, age, and health status in the utilization of health
care. The findings suggested that access to primary care providers was a factor related to
health outcome. For this study, a search of literature from previous studies involving
HPV and oropharyngeal cancer was performed to examine the costs of the disease. The
relationship between HPV and oropharyngeal cancer may provide insight on
interventions for these populations.
Nature of the Study
The study was quantitative in nature and used the Aday and Andersen theory as
the framework to examine the link between HPV and radiation therapy cost associated
with HPV-related oropharyngeal cancer. Cluster sampling was used to randomly select
participants from the head and neck database. The samples were composed of 130 men
and women aged 40-65 years who had been diagnosed with oral cancer. The G*Power
analysis program was used to determine the sample size. The samples included all men
and women diagnosed with HPV-related oropharyngeal cancer. The CDC (2012b)
provided age-based statistics regarding oropharyngeal cancer diagnosis: 62 years old
among women and 59 years old among men. The study assessed the possible relationship
between HPV and the cost of HPV-related oropharyngeal cancer among populations
based on age, gender, insurance, and race in Kentucky. If there is a correlation between
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HPV and increased costs associated with HPV and oropharyngeal cancer, testing and
prevention efforts may be addressed.
Deidentified data were used to evaluate the possible relationship between HPV
and the cost of HPV-related oropharyngeal cancers. The study used descriptive analysis
with correlational, longitudinal data collected over time to examine the relationship of
categorical variables (gender, race, HPV status, insurance) and continuous variable (age)
for oropharyngeal cancer using SPSS Statistics. Logistics regression was used for the
continuous and categorical variables. Multistage random sampling was used to help
generalize to the population. Characteristics used to stratify the population included age,
gender, race, insurance, and HPV status from the head and neck database gathered from
multidisciplinary clinics.
Literature Search Strategy
I searched literature on the prevalence of oropharyngeal cancer and HPV in
Kentucky. I reviewed existing literature on oropharyngeal cancer associated with HPV
based on age, gender, race, and insurance status. Interventions based on knowledge of
HPV as a contributing factor could lower oropharyngeal cancer rates and reduce the
burden of associated costs on health care systems.
I conducted a review of current literature, using the Walden University Library to
access the CINAHL, PubMed, ProQuest, Science Direct, and MedLine databases. Google
Scholar was used to search for literature from the CDC, ACS, National Cancer Database
(NCDB), and National Cancer Institute, Surveillance, Epidemiology, and End Results
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Program (SEER). Key terms used in the literature search included oropharyngeal cancer,
HPV, health care costs, and oropharyngeal cancer and HPV.
Literature Review
The purpose of this literature review is to summarize the relationship between the
independent variables (age, gender, race, and insurance) and the dependent variable (cost)
associated with HPV-related oropharyngeal cancer. The research problem was that HPVrelated oropharyngeal cancer poses an economic burden on health systems in Kentucky.
Based on a review of literature addressing the cost of treating HPV-related oropharyngeal
cancer and relevant factors; the following sections focus on the topics of HPV
prevalence, oropharyngeal cancer, age, gender, race, insurance, and cost.
HPV Prevalence
HPV is the most commonly diagnosed sexually transmitted disease in the United
States (Haddad, 2017). HPV is a DNA virus that infects skin and wet surfaces of the body
(Mount Sinai Hospital [MSH], 2017). There are more than 100 types of HPV and at least
40 HPV types that affect the genital areas. Some cause genital warts and are low risk,
whereas high-risk types cause cervical and other genital cancers. An estimated 492,800
cervical cancers are caused by HPV each year (D’Souza & Dempsey, 2011). HPV 16, 18,
31, and 33 are high-risk genotypes for cervical cancer (Haddad, 2017), and of these highrisk types, HPV 16 accounts for 90% of oral infections (Lewis et al., 2015). Most
sexually active men and women will acquire HPV in their lifetime. HPV, known to cause
cervical cancer, is now being linked to an increase in oropharyngeal cancers.
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According to the National Cancer Institute (NCI, 2017), cancers of the tonsil or
base of tongue are affecting people who are usually at low risk of HPV-related infections.
The epidemiology of oral HPV infection is not quite understood, even though the virus
has been known to cause cancers of the cervical, vulvar, penile, and ano-genital areas
(Osazuwa-Peters et al., 2015). The belief is that there is an increase in people engaging in
sexual activity with multiple partners and an increase in oral sex practices resulting in
contracting HPV in the neck region (Osazuwa-Peters et al., 2015).
Approximately 39,000 newly diagnosed HPV-related cancers were seen between
2008 and 2012 in the United States (CDC, 2016). The most common were cervical
carcinomas and oropharyngeal carcinomas. Of the 39,000 cancers in the United.States,
approximately 30,700 could be associated with HPV (Viens et al., 2016). The CDC
reported that Utah has the lowest rate of HPV-related cancers, with 7.5 cases per 100,000
persons, while Kentucky has the highest, with 14.7 cases per 100,000 persons (CDC,
2016). A study was conducted in Appalachia showing higher incidence rates for HPVrelated cancers for males and females than non- Appalachia males and females (Reiter et
al., 2013). The study suggests that there exist disparities beyond cervical incidence rates,
including oral cavity and pharyngeal cancers.
Oropharyngeal Cancer
Cancers of the oropharynx are on the rise. According to the ACS (2016), oral
cancer is the sixth most common form of cancer in the United States. Areas affected by
oral cancers include the nasal cavity, sinuses, lips, mouth, thyroid glands, salivary glands,
larynx, and pharynx, which are divided into the nasopharynx, oropharynx, and
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hypopharynx (CDC, 2017). In 2013 in the United States, 41,717 people (29,693 men and
12,024 women) were diagnosed with oral cancers (CDC, 2017). Approximately 8,850
people (6,227 men and 2,523 women) died from these diseases (CDC, 2017).
More than 90% of oral and oropharyngeal cancers are squamous cell carcinomas.
The most common locations for these cancers are the tongue, tonsils, oropharynx, gums,
and floor of the mouth. The risk factors for oropharyngeal cancer are tobacco use,
alcohol, prolonged sun exposure, and HPV. Cancers of the tonsils and base of tongue
have become more common due to HPV exposure. Sexual activity, including oral sex, is
the most common way to get HPV.
A U.S. study reported that oral sex was common among women and men but was
most common among people 30-49 years old (D’Souza & Dempsey, 2011). Oral sex was
reported by 86% of 30- to 40-year-old men, 74% of men aged 50-69 years, and 62% of
men aged 70 years or older, compared to 82%, 77%, and 43% of women aged 30-49
years, 50-69 years, and 70 years or older, respectively (D’Souza & Dempsey, 2011;
Herbenick et al., 2010). The progression from HPV infection to malignancy can take up
to 10 years (D’Souza & Dempsey, 2011). A change is sexual behavior could explain the
increase in oral cancers several decades later.
A study conducted in Oklahoma examined trends in oral cancer and
oropharyngeal cancer. The study used data from the Oklahoma Central Cancer Registry
and Surveillance, Epidemiology, and End Results program to compare people diagnosed
from 1997-1999 to those diagnosed from 2010-2012 (Denson et al., 2016). The study
observed differences by race, gender, and age. The findings showed an increase in
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oropharyngeal cancer over time. There was an age-adjusted increase in oropharyngeal
cancer incidence from 3.2 (95% CI: 2.6, 3.8) per 100,000 in 1997 to 5.1 (95% CI: 4.4,
5.8) per 100,000 in 2012 (Denson et al., 2016). The explanation for the increase in
oropharyngeal cancer rates was an increase in HPV prevalence.
Race
Rates of human papillomavirus oropharyngeal cancer vary by race. Cole, Polfus,
and Peters (2012) provided evidence that HPV-associated cancers disproportionately
affect certain age, sex, and race/ethnicity groups. Non-Hispanic Blacks present with
higher incidence of oropharyngeal cancers compared to women and individuals of other
races (Cole et al., 2012). White men have been reported as having the highest rate of
cancers of the oral cavity, followed by Black men (CDC, 2017). There was a significant
increase in HPV-associated neck cancers, whereas non-HPV-associated neck cancers
declined (Cole et al., 2012). The results indicated that Non-Hispanic Whites and
Hispanics represented with greater increases in incidence for HPV-associated sites,
whereas incidence declined among non-Hispanic Blacks independent of HPV association
(Cole et al., 2012).
Human papillomavirus oropharyngeal cancer affects more Whites (21-64%) than
Blacks (0-35%; Rettig, Ponce Keiss, & Fakhry, 2015). Findings from a population-based
study indicated that Whites are more likely to perform oral sex, have more sexual
partners, and engage in sex at a younger age than Blacks (Rettig et al., 2015). Although
oral infections were higher among Blacks in the United .States (10.5%) compared to
Whites (6.5%, p = 0.06), there was no significant difference in the prevalence of

12
infections by race (Rettig et al., 2015). Only oral HPV among men showed higher
incidence in Whites.
Age
Oropharyngeal cancer has been proven to be more prevalent in younger adult
populations without histories of drinking and smoking (Minassian, 2014). A crosssectional study of men and women 14 to 69 years old found that HPV DNA prevalence in
oral exfoliated cells was 6.9%, and the prevalence of HPV 16 was 1% (Jones et al.,
2013). HPV-positive oropharyngeal cancer patients are younger when compared to HPVnegative oropharyngeal cancer patients. The median age was 57 years for HPV-positive
patients, compared to 61 years for HPV-negative patients (O’Sullivan et al., 2016). The
population-level burden is currently unknown for HPV-related oropharyngeal cancer.
This may have important implications for cancer prevention through HPV vaccination
and education.
The National Cancer Institute’s Surveillance, Epidemiology, and End Results
(SEER) population study examined data from 2002 to 2012. It included 149,301 head and
neck cancer cases, with 37,965 being oropharyngeal cancer (Mourad et al., 2017). The
study concluded that patients under 60 years of age made up 59.2% of HPV-related
cancer (Mourad et al., 2017).
Gender
Twice as many men as women are diagnosed with oropharyngeal cancers (CDC,
2017). The SEER population study of data from 2002 to 2012 concluded that the male-tofemale ratio was 4:1 for HPV-related oropharyngeal cancer. The HPV-related
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oropharyngeal cancer rate for men increased by 2.89% per year compared to an
insignificant increase of 0.57% for women (Mourad et al., 2017). A Portugal study
reported an increase of 3.5 annual percentage change (APC) in men with oropharyngeal
cancer (Mourad et al., 2017). Korea reported similar results with an APC of 2.65%
increase for men (Mourad et al., 2017). The findings suggest that more men are
developing HPV-related oropharyngeal cancer, potentially skewing gender distribution.
In contrast, a study in England found increased incidence in men and women (47.1% and
37.5%, respectively; Mourad et al., 2017).
Human papillomavirus is associated with an increase in oropharyngeal cancer in
the United States and other countries. Combes, Chen, and Franceshi (2014) assessed the
results of 63 studies reporting oropharyngeal cancer data by gender. The United States
had the highest male to female ratio of HPV oropharyngeal cancer, while Asia and some
European countries were the lowest (Combes et al., 2014). HPV oropharyngeal cancer for
men was 65.8% in North America and 28.9% in Asia (Combes et al., 2014). In contrast,
Asian women presented highest (61.5%) for HPV oropharyngeal cancer. The
confirmation that HPV oropharyngeal cancer data differ by gender is relevant.
Insurance
The Kentucky Department of Insurance regulates the market that includes
Medicare, Medicaid, commercial insurers, and payment/reimbursement. Kentucky ranks
18th nationally in access to health care, and 9.8% of Kentucky’s population is uninsured
(Bowling, 2016). Kentucky was one of two states to increase Medicaid coverage
following passage of the Affordable Care Act. Approximately 268,000 people gained

14
coverage; the majority were adults 19-64 years old, with Medicaid coverage increasing
by 80% (Bowling, 2016). In 2017, Kentucky’s state-based exchange transitioned to a
federal exchange.
Cancer prevention and screening services are covered under the Affordable Care
Act. Screening services for breast, cervical, colon, lung, and HPV vaccinations for males
and females 11-26 years of age are covered in Kentucky. Routine screening for head and
neck cancer is not covered. A study conducted on patients with neck cancer showed that
Medicaid patients presented with advanced cancer and higher rates of treatment delays
compared to non-Medicaid patients (Naghavi et al., 2016). Oropharyngeal cancer
treatment poses a significant cost for Medicaid, suggesting that early detection may
reduce the economic burden of the disease.
Costs
High treatment costs for oropharyngeal cancer often involve a combination of
surgery, radiation, and chemotherapy. A review of 299 patients diagnosed with
oropharyngeal cancer between 2011 and 2015 revealed 72 patients available for
evaluation to determine costs associated with treatment (Pinheiro & Krama, 2016). Fortytwo patients were treated with surgery and twenty-nine patients were treated without
surgery. Patients treated with surgery alone relative to no surgery had the lowest cost
($38,462, $83,222; Pinheiro & Krama, 2016). Patients who had surgery followed by
chemotherapy/radiation had similar costs compared to patients treated with primary
chemotherapy/radiation ($84,598 vs. $83,222; Pinheiro & Krama, 2016).
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A 2-year study in Texas found the cost of treating oropharyngeal cancer to be
$139,749. The data were extracted from Truven MarketScan Commercial Claims and
Encounter Database from 2011-2004. The data included 467 patients with oropharyngeal
cancer and a control group of 467 noncancer patients. Age, comorbidity, mental health,
prediagnostic cost, and time were predictors of cost (Cavallo, 2017). The findings
showed that the cost of care for oropharyngeal cancer was higher than in previous
studies. The mean cost was $6,693 for people with cancer and $870 for those without
cancer (Cavallo, 2017). The majority of the cost was from outpatient services ($106,604);
inpatient costs and drug costs were $42,341 and $3,550, respectively (Cavallo, 2017).
Ward et al. (2016) provided information on costs associated with HPV-related
oropharyngeal cancer. With 13,000 new cases annually, the estimated mean lifetime cost
per new case of HPV-related cancer is $43,000, which translates to a total cost for the
United States of $306 million (Ward et al., 2016). By vaccinating boys and men, it would
be possible to prevent 5,416 and 43,168 cases of HPV-related oropharyngeal cancer in 50
and 100 years, respectively, due to the latent period between HPV infection and the
development of oropharyngeal cancer (Ward et al., 2016). The costs to vaccinate for HPV
are predicted to be below the $50,000/quality-adjusted life year threshold that determines
the cost-effectiveness of public health initiatives (Ward et al., 2016).
Chesson et al. (2012) provided information on direct costs attributed to HPV.
Their report provided estimated annual costs for screening, follow-up care, and treatment.
Cervical and oropharyngeal cancers account for $1 billion of total costs for HPV-related
cancers (Chesson et al., 2012). A study in France provided by Borget, Abramowitz, &
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Mathevet (2011) provided data on the economic burden of HPV-associated cancers. The
study assessed the annual costs of cancers of the vulva, vagina, anus, penis, and head and
neck. The costs for men were $107.2 million caused by head and neck cancers. The costs
for women were $83.9 million due to cervical cancer. This information is important to
consider for evaluating HPV vaccines for men and women.
A retrospective study consisting of 365 patients 20 years or older assessed median
monthly costs as follows: $2,199 for diagnosis, $4,161 for treatment, $6,614 for end-oflife care, and median total cost $110,793 (Reveles, Reveles, Frei, Frei, & Koeller, 2017).
Costs were driven by outpatient costs (23%), inpatient costs (18%), and radiation therapy
(16%; Reveles et al., 2017).
Data offered by Vanderpool (2016) on Kentucky’s oropharyngeal costs and HPV
vaccination rates suggest that the United States spends approximately $8 billion annually
on HPV-associated disease (Vanderpool, 2016). The average number of oropharyngeal
cancers in the United States each year is 12,638 for males and 3,100 for females (CDC,
2012a; Vanderpool, 2016). The number of oropharyngeal cancers caused by HPV each
year in the United States is 9,100 for males and 2,000 for females (CDC, 2012a;
Vanderpool, 2016). The 5-year invasive incidence rate is 11.0 for the United States and
13.6 for Kentucky. The mortality rates are 2.5 for the United States and 2.8 for Kentucky.
These statistics could provide data for policy recommendations for the Kentucky
population.
Definition of Terms
Terms operationalized by this study include the following:
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Cancer center: Cancer centers carry out laboratory, clinical, and population-based
research. Although most cancer centers provide care for people with cancer, some only
conduct laboratory research (American Society for Clinical Oncology [ASCO], 2017).
Carcinoma: Cancer that begins in the skin or in tissues that line or cover body
organs (Medicine Net, 2018).
Human papillomavirus (HPV): An infection caused by a DNA virus that is spread
through sexual contact and is associated with a range of diseases and cancers (NCI,
2015).
Medicaid: Medicaid provides health coverage to millions of Americans, including
eligible low-income adults, children, pregnant women, elderly adults, and people with
disabilities. Medicaid is administered by states according to federal requirements. The
program is funded jointly by states and the federal government (Centers for Medicare and
Medicaid Services [CMS], 2018).
Medicare: Medicare is a health insurance program for people 65 years of age or
older, people under age 65 with certain disabilities, and people of all ages with end-stage
renal disease (permanent kidney failure requiring dialysis or a kidney transplant; CMS,
2018).
Oropharyngeal cancer: Oropharyngeal cancer is a form of head and neck cancer
that forms in the cells of tissue of the middle part of the throat (pharynx; NCI, n.d., 2015).
Race: A category whereby an individual or group is classified according to
physical features such as skin color that is associated with ancestry and geographic origin
(Templeton, 2013).
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Radiation therapy: Radiation therapy is a type of cancer treatment that uses
beams of intense energy to kill cancer cells (Mayo Clinic, 2018).
Sexually transmitted diseases: Diseases that are passed from one person to
another through intimate physical contact and sexual activity, including vaginal, oral, and
anal sex (CDC, 2017).
Assumptions
In this study, I relied on the following assumptions: The head and neck database
on Kentucky residents included the variables needed to complete the study. I assumed
that there would be enough participants; that all the data is complete; that access would
not be difficult.
Limitations
This study is limited to existing data collected from a Louisville, Kentucky cancer
center between 2010 and 2016. Age, gender, race, insurance, and HPV were the variables
used for the study. Other variables that are associated with oropharyngeal cancer, such as
smoking and drinking were not considered.
Delimitations
I used data from a cancer center in Louisville, Kentucky. No other oropharyngeal
cancer data was used. Men and women in the study are 40-65 years of age. The
participants are residents of Kentucky diagnosed with HPV related oropharyngeal cancer
receiving cancer treatment in Louisville, Ky.
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Significance
The significance of this study was to examine the possibility that HPV
vaccination may impact cost resulting from HPV related oropharyngeal cancers in
Kentucky. Oropharyngeal cancer treatment therapies used to treat oropharyngeal cancer
can result in substantial cost to our healthcare system (Ward et al., 2016). The
oropharynx is the most common site for HPV infection (OCF, 2017). Oral cancers that
were commonly associated with older males and alcohol consumption are now affecting
younger populations regardless of alcohol or tobacco use (OCF, 2017). By 2020, HPV
oral pharyngeal squamous cell carcinoma is projected to outnumber HPV mediated
cervical cancer in the United States (Lewis et al., 2015).
Summary
Oropharyngeal cancer rates are increasing with data suggesting that Human
Papillomavirus (HPV) may be an important causal reason for this rise (D’Souza &
Dempsey, 2012). Oropharyngeal cancers were diagnosed in older males who abuse
tobacco and alcohol, but currently oral cancer is affecting those under the age of 40
(Lewis et al., 2015). Kentucky has some of the highest HPV related cancer rates in the
nation; including oropharyngeal cancer (AE&A, 2017). Therefore, the problem was to
examine the burden of costs associated with treating oropharyngeal cancer in Kentucky.
This study could contribute to a positive social change by addressing HPV and the impact
on health care costs associated with HPV related disease
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Conclusion
Human Papillomavirus that is associated with oropharyngeal cancer is closely
associated with cervical cancer. Ceravix is an approved vaccine that protects against HPV
16. The vaccine was developed to reduce the incidence of ano-genital neoplasms and may
be possible to reduce the incidence of HPV related oral cancers. By 2020, HPV oral
pharyngeal squamous cell carcinoma is projected to outnumber HPV mediated cervical
cancer in the United States (Lewis et al., 2015). Addressing human papillomavirus as a
contributing factor in the increase of oropharyngeal cancers may develop interventions
for cancer prevention strategies.
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Section 2: Research Design and Data Collection
Introduction
The cost associated with radiation therapy treatments for HPV-related
oropharyngeal cancer is substantial. The purpose of this study was to use secondary data
to determine the impact that age, gender, race, and insurance have on the cost of treating
HPV-related oropharyngeal cancer. Section 2 contains explanations of the research
design and data collection method used to examine HPV-related oropharyngeal cancer
costs. In this section, I address the research design, rationale, methodology, data analysis
plan, threats to validity, and ethical procedures in detail.
Research Design and Rationale
For this quantitative research study, I used a head and neck cancer database to
determine the radiation therapy cost for HPV-related oropharyngeal cancer based on age,
gender, race, and insurance. This methodology was appropriate for testing my theory by
examining the relationship among variables. Creswell (2009) stated that quantitative
research design can be used to evaluate relationships among variables. I conducted a
correlational, longitudinal descriptive analysis to evaluate the possible relationship
between HPV-related oropharyngeal cancers and the cost of treating these cancers based
on age, gender, race, and insurance. Retrospective data were used from a head and neck
cancer database. All data were deidentified to avoid ethical concerns and to protect
confidentiality.
In this study, the data allowed for evaluating the extent to which factors affected
the cost of treatments. The independent variables were age, gender, race, and insurance.
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The dependent variable was cost. The use of quantitative methodology was appropriate to
assess the cost of radiation therapy treatments because it provided information about the
relationships between the variables.
There were no resource constraints for this study. There were time constraints
affecting data collection. No data collection took place prior to Institutional Review
Board (IRB) approval.
For this study, there was one research question and two hypotheses:
RQ: Is there a significant predictive relationship between patient age, gender,
insurance type, and race and the increased cost of radiation therapy associated with HPVrelated oropharyngeal cancer in Kentucky?
H1:

There is no significant predictive relationship between patient age, gender,
insurance type, and race and the increased cost of radiation therapy
associated with HPV-related oropharyngeal cancer in Kentucky.

H0:

There is a significant predictive relationship between patient age, gender,
insurance type, and race and the increased cost of radiation therapy
associated with HPV-related oropharyngeal cancer in Kentucky.
Methodology

Secondary Dataset Management
A secondary database from a regional cancer center was used to complete this
study. The data came from a head and neck cancer database. All participants whose
information was included in these data were HPV positive and had been diagnosed with
oropharyngeal cancer between the ages of 40 and 65. I was granted permission to access
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the dataset from the University Medical Center (UMC) Research Office. Researchers
using the database, which contains protected health information, must read and agree to
all terms and conditions relating to the dataset. Consent to use the data was given by the
UMC Research Office.
Sampling and Sampling Procedure
The data were produced from a dataset using a stratified sampling technique. The
multiple strata included HPV, diagnosis of head and neck cancer of the oropharynx, age,
gender, race, insurance, and radiation treatments.
Sample and Population Size
In total, data for 1,654 cases of head and neck cancers were collected. Of the
1,654 head and neck cancers, 628 were diagnosed with oropharyngeal cancer. Out of the
628 cases, 208 tested positive for HPV or p16. The final sample size of 130 participants
was determined by G*Power analysis. A systematic random sampling technique was used
to select the participants based on strata, with equal opportunity of selection within each
stratum.
Inclusion and Exclusion Criteria
All participants in this data collection were HPV positive and had been diagnosed
with oropharyngeal cancer between the ages of 40 and 65. The original data included all
head and neck cancers regardless of HPV status or age. Participants who were under the
age of 40 years, over the age of 65 years, and/or HPV negative were excluded.
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Data Collection Tools
The participants were seen in a multidisciplinary clinic with a positive diagnosis
of head and neck cancer. The data were driven by physicians. The data were assessed
using the National Comprehensive Cancer Network (NCCN) guidelines for the head and
neck cancer workup. The original data included name, medical record number,
consultation, pathology, HPV status, stage, treatment, protocol, vitals, treatment start and
completion date, ears, nose, and throat (ENT) specialist referral, expiration date, and
comments. Testing for HPV and p16 is done as part of the workup that determines
treatment and prognosis. Data have been collected from 2009 to the present to assess the
status, diagnosis, and treatment regimens of participants.
For this study, the participants were selected from the head and neck cancer
database. The data collected for participants that met the selection criteria were from
2010 to 2016. Data were collected on every head and neck cancer patient seen in the head
and neck clinic. The patients had a positive biopsy for cancer diagnosis.
The data collected came from the outpatient electronic medical record (EMR). For
data collection purposes, information was put into a deidentified format with a master list
stored in a separate, password-protected location.
Justification for the Effect Size, Alpha Level, and Power Level
The minimum effect size was chosen to allow for greater external validity due to
this being a stratified multistage cluster study. To reduce Type 1 error, the alpha level
was 0.3, with a power level of 80 to reduce Type 2 error.
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Proposed Data Analysis Plan
I planned to conduct a simple descriptive analysis. Bivariate and multivariate
analyses were used to identify associations between the dependent and independent
variables. A multiple regression analysis was used to reduce statistical errors. I developed
the research question using Aday and Anderson’s theory as a guide for the study.
Research Question and Hypothesis
RQ: Is there a significant predictive relationship between patient age, gender,
insurance type, and race and the increased cost of radiation therapy associated with HPVrelated oropharyngeal cancer in Kentucky?
Ha1:

There is no significant predictive relationship between patient age, gender,
insurance type, and race and the increased cost of radiation therapy
associated with HPV-related oropharyngeal cancer in Kentucky?

Ho1:

There a significant predictive relationship between patient age, gender,
insurance type, and race and the increased cost of radiation therapy
associated with HPV-related oropharyngeal cancer in Kentucky?
Threats to Validity

A limitation was the number of variables available for this analysis. A potential
threat to internal validity was the selection of variables and data collection. To reduce
threats to statistical conclusion validity, a significance value of p < .05 was used to assess
the association between variables. The reduction of threats was validated using SPSS.
There was no threat to external validity. Data were collected from one regional Kentucky
cancer center and can be generalized to a larger population.
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Ethical Considerations
This study contains an analysis of a secondary dataset observing variable
collected from the head and neck clinic at a regional cancer center. All participants are
anonymous, and I had no direct contact with the participants in this study. IRB approval
was obtained for this study from the University Medical Center on May 30, 2018, with
the approval number of 18.0500. IRB approval was also given from Walden University
on June 6, 2018, with the approval number of 06-04-18-0637405.
Summary
In this chapter, I explained the research design, rationale, and methodology of the
study. The sampling and sampling procedures, data collection, secondary data
management, and data analysis plan were explained.
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Section 3: Presentation of the Findings and Results
Introduction
The purpose of this quantitative correlational research design was to evaluate the
relationship between age, gender, race, insurance, and radiation therapy cost for HPVrelated oropharyngeal cancer in Kentucky. HPV has been linked to an increase in
oropharyngeal cancers. A dataset covering the years 2010-2016 was collected from a
head and neck cancer database. A review of literature revealed few studies assessing
state-specific costs of treating HPV-related oropharyngeal cancer.
Descriptive Statistics
The study included four independent variables and one dependent variable. The
independent variables were patient gender, patient race, type of insurance for the patient,
and age. Originally, the dependent variable was the cost difference, computed as the
difference between the total cost for the patient and the estimated cost.
Table 1 shows the gender of the patients. Of the 130 patients, most were male
(83.1% male, 16.9% female).
Table 1
Frequency Table for Gender of Patient

Valid

Male
Female
Total

Frequency
108
22
130

Percent
83.1
16.9
100.0

Valid percent
83.1
16.9
100.0

Cumulative
percent
83.1
100.0
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Nearly three-fourths of all patients (74.8%) were covered by private insurance.
Another 15.7% paid for treatment using Medicare or Medicaid, and 9.4% were covered
by other government insurance (see Table 2).
Table 2
Frequency Table for Insurance Type Used by Patient

Valid

Medicare/Medicaid
Private insurance
Other government insurance
Total
Missing -1.00
Total

Frequency
20
95
12
127
3
130

Percent
15.4
73.1
9.2
97.7
2.3
100.0

Valid
percent
15.7
74.8
9.4
100.0

Cumulative
percent
15.7
90.6
100.0

Table 3 shows that over 9 of 10 patients were White (91.5%); while (8.5%) were
members of racial/ethnic minority groups.
Table 3
Frequency Table for Race of Patient

Valid

White
Minority
Total

Frequency
119
11
130

Percent
91.5
8.5
100.0

Table 4 shows the percentages for age groups.

Valid percent
91.5
8.5
100.0

Cumulative
percent
91.5
100.0
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Table 4
Frequency Table for Patient Age Group

Valid Under 50 years old
50 to 59 years old
60 years and older
Total

Frequency
13
55
62
130

Percent
10.0
42.3
47.7
100.0

Valid
percent
10.0
42.3
47.7
100.0

Cumulative
percent
10.0
52.3
100.0

Descriptive statistics for cost difference are listed in Table 5. The mean cost for
radiation therapy treatment was $123,629.14 (SD = $58,697.36).
Table 5
Descriptive Statistics for Cost Difference Variable
Variable
N

Valid
Missing

Mean
Std. error of mean
Median
Std. deviation
Variance
Skewness
Std. error of skewness
Kurtosis
Std. error of kurtosis
Range
Minimum
Maximum
Percentiles 25
50
75

Value
129
1
123629.14
5168.02
142376.00
58697.36
3445379605.61
-.60
.21
.58
.42
320537.76
198.24
320736.00
92586.50
142376.00
156984.00
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Figure 1 provides a boxplot of the cost difference dependent variable. There was
one outlier, and it was evident that the mean value was not part of a normal distribution.
The boxplot provided evidence of the need to normalize the dependent variable using the
z score of cost difference.

Figure 1. Boxplot of cost difference.
Another method to test the dataset for normality was to create a histogram and
evaluate the skewness and kurtosis values associated with the frequency
distribution/histogram (see Figure 2). The histograms and skewness value indicated that
the distribution for cost difference variable was slightly skewed to left.
After the visual inspection of the distribution, the statistical method to test for
normality of the dependent variable is the Kolmogorov-Smirnoff test (K-S) when the
sample size is 50 or greater.
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Figure 2. Histogram for cost difference.
The z score for cost difference was developed because the distribution for cost
difference was not normally distributed [K-S (129) = 0.215, p < 0.01] (see Table 6).
Table 6
Tests of Normality for Dependent Variable
Kolmogorov-Smirnova
Shapiro-Wilk
Statistic
df
Sig.
Statistic
df
Sig.
.239
129
.000
.856
129
.000

Sum of charge—Total
charge
Sum of estimated.192
charge payments
Cost difference
.215
a
Lilliefors significance correction.

129

.000

.802

129

.000

129

.000

.881

129

.000

In Figure 3, the z score for cost difference appears normally distributed. In the
next section, I begin inferential statistics to test the hypotheses for each research question.
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Figure 3. Histogram for z score of cost difference.
Inferential Statistics: Testing the Hypotheses
RQ. Is there a significant predictive relationship between patient gender, age,
insurance type, and race and the increased patient cost associated with HPV-related
oropharyngeal cancer in Kentucky?
H01:

There is no significant predictive relationship between patient gender, age,
insurance type, and race and the increased patient cost associated with
HPV-related oropharyngeal cancer in Kentucky.

Ha1:

There is a significant predictive relationship between patient gender, age,
insurance type, and race and the increased patient cost associated with
HPV-related oropharyngeal cancer in Kentucky.

To test the hypotheses for the research question, a multiple regression was
performed to predict the dependent variable z score of cost differences from a set of
independent predictor variables for patient gender (male/female), patient age (under
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50/50-65/over 65), type of insurance (Medicare-Medicaid/private insurance/other
government insurance), and race (minority/White).
There were 130 patients studied, with 127 valid responses without missing data.
From Table 7, the dependent variable of z score of cost difference was normally
distributed, with mean = 0 and standard deviation = 1.0.
Table 7
Descriptive Statistics of z Score of Cost Difference

z score of cost difference

Mean
.0000

Std. deviation
1.00000

N
127

The residual results are shown in Figures 4-8. These include a plot of normality,
a scatterplot of the predicted and standardized residuals, and a histogram of the
standardized residuals. Figure 4 presents a histogram of the residuals with a normal curve
superimposed. The residuals appear close to normally distributed in Figure 5. The
standardized residual plots show a random scatter of points with constant variability (see
Figure 6 and 7). This was verified in Figure 8 with the linearity of the scatterplot. In fact,
the range of values predicted by the model was wide (minimum predicted value = -0.318,
maximum = 0.457).
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Figure 4. Histogram of z score of cost difference as dependent variable.

Figure 5. Normal P-P plot of standardized residuals: z score of cost difference as
dependent variable.
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Figure 6. Scatterplot of standardized predicted value by standardized residuals.

Figure 7. Scatterplot of standardized predicted value by z score of cost difference
(dependent variable).
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Figure 8. Scatterplot of standardized residuals by z score of cost difference (dependent
variable).
A correlation matrix (see Table 8) was part of the multiple regression output so
that preliminary issues with multicollinearity between independent predictor variables
could be determined. Based on the correlations, it does not appear to be an issue.
However, only the evaluation of tolerance values or VIF values can determine
multicollinearity concerns in the final model.
The multiple regression model was built using the Enter method for entering and
removing variables from the equation. The summary table (Table 9) indicated various
diagnostic results for the multiple regression model including the coefficient of
determination R2. The coefficient of determination R2 demonstrates that only 3.1% of the
change in the variance of the z score of cost difference can be explained by the
independent predictor variables of gender, age, insurance type, and race.
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Table 8
Correlation Matrix

z score of cost
difference

Pearson
correlation
Sig. (1-tail)
Gender
N
Pearson
correlation
Sig. (1-tail)
Race with two N
groups
Pearson
correlation
Insurance
Sig. (1-tail)
reduced to
N
three
categories
Pearson
correlation
Sig. (1-tail)
N

Race
with two
Gender groups
-.051
.085
.283
.171
127
127

Insurance
reduced to
three
categories
-.106
.117
127

Recode
age into
groups
-.021
.407
127

-.029
.374
127

.002
.491
127

.208
.010
127

-.175
.024
127

.240
.003
127

-.166
.031
127

Table 9
Multiple Regression Model Summary: z Score of Cost Difference as Dependent Variable

Change statistics
Model
1

R
.176

a

R

Adjusted R

Std. error of the

R square

square

square

estimate

change

.031

-.001

1.00044

.031

F

Sig. F

change df1 df2
.972

4

122

change
.425

Note. Predictors: (Constant), Recode age into groups, Gender, Insurance reduced to three categories, Race
with two groups.
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Table 10 indicates that the regression model was not statistically significant. The
null hypothesis was accepted that the independent variables were not statistically
significant predictors of the z Score of Cost Difference [F (4,122) = 0.972, p = 0.425].
Table 10
Multiple Regression ANOVA Table: z Score of Cost Difference as Dependent Variable

Sum of
Model
squares
df
Mean square
F
Sig.
1
Regression
3.892
4
.973
.972
.425a
Residual
122.108
122
1.001
Total
126.000
126
Note. Predictors: (Constant), Recode age into groups, Gender, Insurance reduced to three
categories, Race with two groups.
The model coefficients and significance level for each of the independent
variables are displayed in Table 11. There were no significant independent predictor
variables (p > 0.05); gender [t (127) = -0.943, p = 0.348], race [t (127) = 1.378, p =
0.171], insurance type [t (127) = -1.512, p = 0.133], and age group [t (127) = -0.230, p =
0.818]. The model constant was also not statistically significant [t (127) =0.582, p =
0.561]. The table also shows that the tolerance values are close to 1 and not near zero so
there was no multicollinearity.
The standardized regression coefficients () are used to express the relationship
between each significant predictor variable and the dependent variable. The  values
were not statistically significant for any predictor independent variables.
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Table 11
Multiple Regression Coefficients: z Score of Cost Difference as Dependent Variable

Unstandardized

Standardized

95.0% confidence

coefficients

coefficients

interval for B

Model

B

Std. error

(Constant)

.382

.656

Gender

-.233

.247

Race

.465

Insurance

Beta

Lower

Upper

t

Sig.

bound

bound

.582

.561

-.916

1.680

-.087

-.943

.348

-.722

.337

.131

1.378

.171

-.279

.184

-.139

-1.512

-.032

.137

-.021

-.230

Collinearity statistics

Tolerance

VIF

.256

.935

1.070

-.203

1.132

.876

1.141

.133

-.644

.086

.934

1.071

.818

-.303

.240

.950

1.052

type
Age
group

A summary of the residuals that result from the predictor model are found in
Table 12. The value for the residuals (M = 0.00, SD = 0.984) relates to the low R2 value,
the lack of predictability; however, it does show that the residuals are normally
distributed, which supports the regression assumption of homoscedasticity.
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Table 12
Multiple Regression Collinearity Table: z Score of Cost Difference as Dependent
Variable

Variance proportions
Insurance
Condition
Model Dimension Eigenvalue
1

index

Race

reduced to

Recode

with two

three

age into

groups

categories

groups

(Constant) Gender

1

4.770

1.000

.00

.00

.00

.00

.00

2

.090

7.294

.00

.08

.10

.03

.53

3

.081

7.662

.00

.64

.01

.26

.00

4

.044

10.357

.00

.20

.72

.40

.02

5

.014

18.281

1.00

.08

.17

.31

.45

Table 13
Multiple Regression Residuals: z Score of Cost Difference as Dependent Variable

Predicted value
Residual
Std. predicted value
Std. residual

Minimum Maximum
-.3178
.4573
-2.46661
3.45904
-1.808
2.602
-2.466
3.458

Mean
.0000
.00000
.000
.000

Std. deviation
.17574
.98444
1.000
.984

N
127
127
127
127

Gender was analyzed using an independent samples t-test to determine whether
there was a significant difference in the mean z score for cost difference for between male
and female patients. First, Figure 9 was prepared to display an error bar plot of the mean
z score of cost difference by gender of the patient. The error bar plot was used prior to the
independent t-test as a preliminary determination of whether there was no difference in
the means and variances between the two groups. The x-axis represents the two groups
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from the independent variable (no/yes) and the y-axis represents the mean value of the
dependent variable.
In each error bar, the dot represents the mean of the group. The mean was read by
placing a horizontal line across to the left to the y-axis and reading the value for that
group. The vertical distance between the two horizontal lines in each error bar was the
variance.
The closer in value the means the more likely the assumption of equal means will
prove true when conducting the t-test. The more similar the vertical distance between the
horizontal bars for each group, the more likely Levene’s test of homogeneity of variance
holds true. From the error bar plot, it appears that the means are slightly different. It also
appears that the variance for the z score of cost difference in the female group was greater
than in the male group. It was thought that the independent t-test might show significant
differences in means and variances.

Figure 9. Error bar plot of mean z score of cost difference by gender.
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Next, a table of summary descriptive statistics was constructed for the level of the
dependent variable for male and female patients. These results are found in Table 14
below.
Table 14
Group Descriptive Statistics: z Score of Cost Difference by Patient Gender

z score of cost
difference

Gender
Male
Female

N
107
22

Mean
.0021
-.2091

Std. deviation Std. error mean
1.01976
.09858
1.07738
.22970

Table 15 presents the results from the Levene’s test of equal variances and the
independent sample t-test for testing the null hypothesis that mean z score for cost
difference for both male and female patients are equal.
The Levene’s test of homogeneity of variance exhibits that there was no
significant difference in the level of variance between male and female patients [F (127)
=1.177, p = 0.280]. Therefore, equal variances are assumed. Based on the results of the
independent samples t-test in Table 15, there was no statistically significant difference in
the mean z score of cost difference between male and female patients. The null
hypothesis was accepted [t (127) =-0.876, p = 0.383].
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Table 15
Independent Samples Test and Levene’s Test: z Score of Cost Difference by Patient
Gender

Levene's test
for equality of
variances

t test for equality of means
Sig.
(2-

F
z score of

Equal

cost

variances

difference

assumed

Sig.

1.177 .280

Equal

t
.876

df
127

.845 29.253

95% confidence interval of
Mean

tailed) difference

the difference
Std. error difference

.383

.21116

.405

.21116 .24996

.24100

Lower
-.26575

-.29988

Upper
.68806

.72219

variances
not
assumed

To test the hypotheses of age, a one-way ANOVA was constructed because there
were three groups for patient age. The dependent variable was the z score for cost
differences in treatment. First, an error bar plot was created.
Figure 10 displays an error bar plot of the mean z score of cost difference by age
group of the patient. An error bar plot was used prior to the independent t-test as a
preliminary determination of whether there was no difference in the means and variances
between the two groups. From the error bar plot in Figure 10, it appeared that the mean z
scores for cost difference were slightly different. It also appears that the variance for the
z score of cost difference in the under 50-year old group was greater than in the other two
age groups. We might expect that the independent t-test might show a significant
difference in the variances between the three age groups.
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Figure 10. Error bar plot of mean z score of cost difference by age group.
Next, the one-way ANOVA provided a table of summary descriptive statistics for
the level of the dependent variable for the three patient age groups. These results were
found in Table 16.
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Table 16
Group Descriptive Statistics: z Score of Cost Difference by Patient Age

95% confidence interval for mean
N

Mean

Std. deviation

Std. error

Lower bound

Upper bound

13

.1660

1.07571

.29835

-.4841

.8160

-2.18

1.50

50 to 59

54

-.0875

.99887

.13593

-.3602

.1851

-2.20

1.15

60 years

62

-.0291

1.05565

.13407

-.2972

.2390

-2.19

3.42

129

-.0339

1.02858

.09056

-.2131

.1453

-2.20

3.42

1.03412

.09105

-.2141

.1463

.09105a

-.4257a

.3578a

Under 50

Minimum Maximum

years old

and older
Total
Model

Fixed
effects
Random
effects

Levene’s test indicated the difference in the variation of z score cost differences
based on age group was not statistically significant [F (2, 126) = 0.007, p = 0.993] (see
Table 17). The one-way ANOVA assumption of equal variances held (see Table 18).
Table 17
Levene’s Test of Equal Variances: z Score of Cost Difference by Patient Age

z score of cost
difference

Based on mean
Based on median
Based on median and with
adjusted df
Based on trimmed mean

Levene
statistic
.007
.169
.169
.041

df1 df2
2
126
2
126
2 124.815
2

126

Sig.
.993
.845
.845
.960
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Table 18 indicated that the one-way ANOVA was not statistically significant and
that there was no significant difference in the mean z score of cost differences based on
the patient’s age. Therefore, the null hypothesis was accepted [F (2,126) = 0.316, p =
0.730].
Table 18
one-way ANOVA Results for z Score of Cost Difference by Patient Age Group
Sum of squares df Mean square
Between groups (Combined)
.676
2
.338
Linear term Unweighted
.409
1
.409
Weighted
.094
1
.094
Deviation
.582
1
.582
Within groups
134.745
126
1.069
Total
135.421
128

F
.316
.382
.088
.544

This is also verified by the means plot in Figure 11. The effect size, calculated using eta
squared which was calculated as the sum of squares between groups divided by total sum
of squares, was .005. According to Cohen (1988), there was only a small effect of the
one-way ANOVA.
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Figure 11. Means plots for z score of cost difference by patient age group.
To test insurance type, a one-way ANOVA was constructed because there were
three groups for patient insurance type. The dependent variable was the z score for cost
differences in treatment. First, an error bar plot was created.
Figure 12 displays an error bar plot of the mean z score of cost difference by the
patient’s type of insurance. An error bar plot was used prior to the independent t-test as a
preliminary determination of whether there was no difference in the means and variances
between the two groups. Evaluating Figure 12, it appeared that the mean z scores of cost
difference were slightly different based on the patient’s insurance. It also appears that the
variance for the z score of cost difference for the other government insurance group was
greater than for the private insurance or Medicare/Medicaid insurance groups. We might
expect that the independent t-test might show significant differences in variances but not
the means for z score of cost differences.
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Figure 12. Error bar plot of mean z score of cost difference by insurance type.
The next table, Table 19, provided descriptive statistics for the z score of cost
differences for each of the three types of patient insurance.
Table 19
Group Descriptive Statistics: z Score of Cost Difference by Patient Insurance Type
Std.

95% confidence interval for mean

N

Mean

deviation

Std. error

Lower bound

Upper bound

Medicare/Medicaid

20

.0342

1.00793

.22538

-.4375

.5059

Private insurance

95

.0560

.96740

.09925

-.1411

.2531

Other government insurance 12

-.5003

1.18330

.34159

-1.2521

.2515

Total

.0000

1.00000

.08874

-.1756

.1756

.99464

.08826

-.1747

.1747

.15249

-.6561

.6561

Model

127
Fixed effects
Random effects

The one-way ANOVA assumption of equal variances held (see Table 20).
Levene’s test indicated the difference in the variation of z score cost differences based on
patient insurance type was not statistically significant [F(2, 124) = 1.278, p = 0.282].
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Table 20
Levene’s Test of Equal Variances: z Score of Cost Difference by Patient Insurance Type

z score of cost
difference

Based on mean
Based on median
Based on median and
with adjusted df
Based on trimmed
mean

Levene
statistic df1
1.278
2
1.417
2
1.417
2
1.344

df2
124
124
122.062

Sig.
.282
.246
.246

124

.265

2

Table 21 showed that the One-Way ANOVA was not statistically significant and
that there was no significant difference in the mean z score of cost differences based on
the patient’s type of insurance. Therefore, the null hypothesis was accepted [F (2,126)
=1.663, p = 0.191].
Table 21
One-Way ANOVA Results for z Score of Cost Difference by Patient Insurance Type

Between
groups

(Combined)
Linear
Unweighted
term
Weighted
Deviation

Within groups
Total

Sum of
squares
3.325
2.143
1.420
1.905
122.675
126.000

df
2
1
1
1
124
126

Mean
square
1.663
2.143
1.420
1.905
.989

F
1.680
2.166
1.436
1.925

Sig.
.191
.144
.233
.168

This is also verified by the means plot in Figure 13. The effect size, calculated
using eta squared which was calculated as the sum of squares between groups divided by
total sum of squares, was 0.03. According to Cohen (1988), there was only a small effect
of the one-way ANOVA.
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Figure 13. Means plots for z score of cost difference by patient insurance type.
Race was analyzed using an independent samples t-test to determine whether
there was a significant difference in the mean z score for cost difference based on patient
race. Prior to this inferential test, Figure 14 was generated to provide an error bar plot of
the mean z score of cost difference by race of the patient. An error bar plot was used prior
to the independent t-test as a preliminary determination of whether there was no
difference in the means and variances between the two groups. From the error bar plot, it
appears that the means for minority and white patients are slightly different. It also
appears that the variance for the z score of cost difference in the minority patient group
was greater than in the white patient group. We might expect that the independent t-test
shows no significant difference in means but a significant difference in variances.
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Figure 14. Error bar plot of mean z score of cost difference by race.
Next, I provided a table of summary descriptive statistics for the level of the
dependent variable for white and minority patients. These results are found in Table 22
below.
Table 22
Group Descriptive Statistics: z Score of Cost Difference by Patient Race

z score of cost
difference

Race with two groups N
White
118
Minority
11

Mean
-.0627
.2753

Std.
deviation
1.03491
.94649

Std. error
mean
.09527
.28538

Table 23 presents the results from the Levene’s test of equal variances and the
independent sample t-test for testing the null hypothesis that mean z score for cost
difference for both minority and white patients are equal.
The Levene’s test of homogeneity of variance exhibits that there was no
significant difference in the level of variance between minority and white patients [F
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(127) = 0.256, p = 0.614]. Therefore, the assumption of homogeneity of variances holds.
Based on the results of the independent samples t-test in Table 24, there was no
statistically significant difference in the mean z score of cost difference between minority
and white patients. The null hypothesis was accepted [t (127) =--1.043, p = 0.299].
Table 23
Independent Samples Test and Levene’s Test: z Score of Cost Difference by Patient Race

Levene's test
for equality
of variances

t test for equality of means
95% confidence
interval of the
Sig. (2-

z score of cost

Equal

difference

variances

Std. error

difference

F

Sig.

t

df

tailed)

Mean difference

difference

Lower

Upper

.256

.614

-1.043

127

.299

-.338

.324

-.9795

.3033

-1.124

12.34

.283

-.338

.301

-.9916

.3154

assumed
Equal
variances
not
assumed

Summary
The results presented in this quantitative retrospective study were an analysis of
the head and neck dataset. A total population of 1654 cases of head and neck cancers was
collected. Of the 1654 head and neck cancers, 628 were diagnosed with oropharyngeal
cancer. Out of the 628 cases, 208 tested positive for HPV or p16. I used a multiple
regression analysis to identify and evaluate the associations between the dependent and
independent variables. The analysis revealed that the null hypothesis was accepted and
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the alternate hypothesis was rejected. There was not a statistically significant relationship
between cost and gender [t (127) = -0.943, p = 0.348], race [t (127) = 1.378, p = 0.171],
insurance type [t (127) = -1.512, p = 0.133], and age group [t (127) = -0.230, p = 0.818].
Chapter 4 includes the interpretation, limitation, recommendations, implications for
social change, and conclusions of the study.
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Section 4: Application to Professional Practice and Implications for Social Change
Introduction
Human papillomavirus has been linked to an increase in oropharyngeal cancers.
The cost associated with radiation therapy treatments for HPV-related oropharyngeal
cancer is substantial. The purpose of this quantitative correlational research was to
evaluate the relationship between age, gender, race, insurance, and radiation therapy cost
for HPV-related oropharyngeal cancer in Kentucky.
Concise Summary of Results
I used secondary data from a regional cancer center to complete this study. The
participants were selected from a head and neck cancer database for the period 2010 to
2016. A total of 1,654 cases of head and neck cancers were collected; of the 1,654 head
and neck cancers, 628 were diagnosed with oropharyngeal cancer. Out of the 628 cases,
208 tested positive for HPV or p16. There were 130 patients studied, with 127 valid
responses without missing data. The data were collected and analyzed using logistic
regression, t test, and one-way ANOVA. The research question and hypotheses were
developed to find any association between the dependent variable (cost) and independent
variables (age, gender, race, and insurance). The null hypothesis was accepted, in that the
independent variables were not statistically significant predictors of the z score of cost
difference [F (4,122) = 0.972, p = 0.425]. The results showed no significant independent
predictor variables (p > 0.05); gender [t (127) = -0.943, p = 0.348], race [t (127) = 1.378,
p = 0.171], insurance type [t (127) = -1.512, p = 0.133], and age group [t (127) = -0.230,
p = 0.818]).
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Interpretation of the Findings
Oropharyngeal cancer is the second most common HPV-associated cancer
deserving attention for future interventions (CDC, 2017). Research has demonstrated the
cost of treating oropharyngeal cancer on a national level. Little research has been
completed on state-specific data. Kentucky’s population demonstrates a higher incidence
of HPV-related oropharyngeal cancer compared to other states (CDC, 2017).
The interpretations of the results were generated from a correlation matrix and
multiple regressions to test the hypothesis concerning whether the independent variables
were statistically significant predictors of cost difference for treatment. To test the
hypotheses for the research question, a multiple regression was performed to predict
values on the dependent or criterion variable, the z score of cost differences, from a set of
independent predictor variables for patient gender (male/female), patient age (under
50/50-65/over 65), type of insurance (Medicare-Medicaid/private insurance/other
government insurance), and race (minority/White).
Although the findings were not significant, previous literature demonstrated
similar factors pertaining to HPV-related oropharyngeal cancer. This study showed that 9
of 10 patients were aged under 50 (10%), 50 to 59 years old (42.3%), and 60 years and
older (47.7%) compared to the median age of 57 years for HPV-positive patients in other
studies (O’Sullivan et al., 2016). The NCI SEER population study examined data from
2002 to 2012. The study concluded that patients under 60 years of age make up 59.2% of
HPV-related cancers (Mourad et al., 2017).
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Over 9 of 10 patients were White (91.5%), while (8.5%) were members of
racial/ethnic minority groups. In a previous study, Cole et al. (2012) provided evidence
that HPV-associated cancers disproportionately affect certain age, sex, and race/ethnicity
groups. White men had the highest rate of cancers of the oral cavity, followed by Black
men (CDC, 2017). Human papillomavirus oropharyngeal cancer affects Whites (21-64%)
to a greater extent than Blacks (0-35%; (Rettig et al., 2015).
SEER population study data for the period 2002 to 2012 indicated a male-tofemale ratio of 4:1 for HPV-related oropharyngeal cancer. A Portugal study reported an
increase of 3.5 APC in men with oropharyngeal cancer (Mourad et al., 2017). Korea
reported similar results, with an APC of 2.65% increase for men (Mourad et al., 2017). In
contrast, a study in England found increases in incidence in men and women (47.1% and
37.5%, respectively; Mourad et al., 2017). The percentage of HPV oropharyngeal cancer
cases occurring in men has been reported as 65.8% in North America and 28.9% in Asia
(Combes et al., 2017). In Asia, women had the highest incidence of HPV oropharyngeal
cancer, representing 61.5% of cases. Of the 130 patients in this study, most were male
(83.1% male, 16.9% female).
Nearly three-fourths of all patients (74.8%) were covered by private insurance.
Another 15.7% paid for treatment using Medicare or Medicaid, and 9.4% were covered
by other government insurance. Kentucky ranks 18th in access to health care, and 9.8% of
Kentucky’s population is uninsured (Bowling, 2016). From 2013 to 2014, approximately
268,000 people gained coverage, increasing Medicaid coverage by 80%; the majority of
these newly insured individuals were adults 19-64 years old (Yelowitz, 2016). A study
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conducted on patients with neck cancer showed that Medicaid patients present with
advanced cancer and higher rates of treatment delays compared to non-Medicaid patients
(Naghavi et al., 2016). Oropharyngeal cancer treatment poses a significant cost for
Medicaid, suggesting that early detection may reduce the economic burden of the disease.
The mean cost for radiation therapy treatments in this study was $123,629.14 (SD
= $58,697.36). A review of 299 patients diagnosed with oropharyngeal cancer between
2011 and 2015 revealed 72 patients available for evaluation to determine costs associated
with treatment (Pinheiro & Krama, 2016). The average cost for radiation treatments was
$83,222. A study in Texas found that the cost of treating oropharyngeal cancer was
$106,604. The findings showed that the cost of care for oropharyngeal cancer was higher
than in previous studies. The mean adjusted monthly health care cost for those with
oropharyngeal cancer was $6,693 and $870 for those without cancer (Cavallo, 2017).
Age, comorbidity, mental health, prediagnostic cost, and time were predictors of cost
(Cavallo, 2017). A retrospective study consisting of 365 patients 20 years or older
assessed median monthly costs as follows: diagnosis ($2,199), treatment ($4,161), end of
life ($6,614), and total ($4,167; (Reveles et al., 2017). Costs were driven by outpatient
costs (23%), inpatient costs (18%), and radiation therapy (16%; (Reveles et al., 2017).
The findings of this study demonstrated that age, gender, race, and insurance do
not influence the cost of radiation therapy treatments for HPV-related oropharyngeal
cancer. The statistical analysis from this study demonstrated no relationship between the
independent variables (age, gender, race, and insurance) and the dependent variable
(cost). There were no significant independent predictor variables (p > 0.05); gender
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[t(127 ) = -0.943, p=0.348], race [t(127 ) = 1.378, p=0.171], insurance type [t(127 ) = 1.512, p=0.133], and age group [t(127 )= -0.230, p=0.818].
Aday and Andersen’s (1974) theory may be used in explaining costs related to
predisposing factors, enabling factors, and need factors. The independent variables for
this study were the predisposing factors of age, race, gender, and HPV status; the
enabling factor of insurance; and the needs factor of oropharyngeal cancer. The
dependent variable was cost. The findings disconfirm the theory that cost is influenced by
predisposing, enabling, and need factors.
Limitations of the Study
The objective of this study was to determine whether age, gender, race, and
insurance affected radiation therapy costs associated with treating HPV-related
oropharyngeal cancer. Some limitations of the study were the sample size, selection of
variables, and data from one regional cancer center in Kentucky. A larger sample size,
expansion of the sample to include additional facilities, and consideration of other factors
such as alcohol and tobacco as casual factors in oropharyngeal cancer might have led to
different results. Inclusion of these factors might have supported the findings by making
it possible to generalize to a population outside the sample.
Recommendations
This retrospective study did not examine all factors that could lead to increased
cost associated with treating HPV-related oropharyngeal cancer. Cancer staging and
treatment cost for chemotherapy and surgery were not considered for this study. In the
future, a study with a larger sample size representing other cancer centers in Kentucky
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could be helpful in assessing the cost of radiation therapy treatments for HPV-related
oropharyngeal cancer. In addition, future studies comparing smoking, alcohol, and HPV
status among oropharyngeal cancer cases by gender, race, and age are recommended to
help in understanding these risk factors. There is a need for future studies to evaluate all
HPV-related cancers and the issue of HPV vaccinations.
Implications for Professional Practice and Social Change
Professional Practice
Therapies used to treat oropharyngeal cancer can result in substantial cost to the
healthcare system (Ward et al., 2016). Oral cancers that were commonly associated with
older males and alcohol consumption are now affecting younger populations regardless
of alcohol or tobacco use (OCF, 2017). HPV-positive cancers have a different clinical
presentation compared to HPV-negative cancers. The treatment response and survival
outcome have a favorable prognosis (Chung & Gillison, 2009). Understanding clinical
behavior of HPV-positive cancers may improve disease prevention and strategies for
head and neck cancer patients (Chung & Gillison, 2009). Knowledge and experiences
involving HPV vary across health professionals (Dodd, Foster, Waller, & Marlow, 2017).
Addressing gaps in knowledge among health professionals may help with discussions and
minimize negative psychosocial consequences of the disease.
Social Change
By 2020, cases of HPV oral pharyngeal squamous cell carcinoma are projected to
outnumber HPV-mediated cervical cancer in the United States (Lewis et al., 2015). The
importance of this finding involves the evaluation of HPV vaccination for prevention of
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oropharyngeal cancer. From a health perspective, vaccinating boys has the potential to
reduce the risk of HPV infection of sexual partners. Lowering HPV infection rates in the
general population could lead to lower rates of HPV-related diseases for both genders
(Lee & Garland, 2017). This study could contribute to positive social change by
addressing HPV and the impact on health care costs associated with HPV-related disease.
Conclusion
This quantitative, correlational study examined whether age, gender, race, and
insurance were associated with increased cost of radiation therapy treatments for HPVrelated oropharyngeal cancer. The results of the logistic regression showed no statistically
significant correlation between age, gender, race, and insurance on radiation therapy cost.
While this study did not show an association between these factors and cost, addressing
human papillomavirus as a contributing factor in the increase of oropharyngeal cancers
may promote the development of interventions for cancer prevention while reducing the
economic burden of oropharyngeal cancers.
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